Hanall Biopharma Co., Ltd. (KRX:009420)

South Korea · Delayed Price · Currency is KRW

54,100

-1,500 (-2.70%)

Aug 7, 2026, 3:30 PM KST

Hanall Biopharma Financials Overview

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	159,065	155,185	138,944	134,910	109,995	101,594
Revenue Growth	12.81%	11.69%	2.99%	22.65%	8.27%	14.66%
Gross Profit	82,890	80,775	73,206	75,040	61,876	60,231
Operating Income	-378.22	-1,611	230.47	1,743	1,506	10,099
Net Income	-5,077	-5,559	-1,805	3,509	251.47	8,896
Earnings Per Share	-100.52	-109.48	-35.59	69.21	4.95	173.74
EPS Growth	-	-	-	1298.63%	-97.15%	-55.01%

Revenue by Geography

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Export	7,797	6,851	70.63	35.74	16.07
South Korea	147,387	132,093	134,839	109,960	101,578
Total	155,185	138,944	134,910	109,995	101,594

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	36,158	24,743	24,706	56,497	53,934	80,570
Total Debt	44,196	31,917	1,448	1,291	1,310	1,335
Net Cash (Debt)	-8,038	-7,174	23,259	55,207	52,624	79,234
Net Cash Growth	-	-	-57.87%	4.91%	-33.59%	-12.11%
Net Cash Per Share	-159.16	-141.28	458.63	1089.06	1035.58	1547.46

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	-732.36	-2,340	9,360	29,643	25,264	839.87
Capital Expenditures	-1,352	-948	-1,642	-2,412	-2,830	-4,606
Free Cash Flow	-2,084	-3,288	7,718	27,231	22,434	-3,766
Free Cash Flow Growth	-	-	-71.66%	21.38%	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	52.11%	52.05%	52.69%	55.62%	56.25%	59.29%
Operating Margin	-0.24%	-1.04%	0.17%	1.29%	1.37%	9.94%
Pretax Margin	-3.27%	-3.98%	-0.13%	2.37%	1.75%	8.57%
Profit Margin	-3.19%	-3.58%	-1.30%	2.60%	0.23%	8.76%
FCF Margin	-1.31%	-2.12%	5.56%	20.18%	20.39%	-3.71%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 8, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	-	-	-	640.06	3588.03	121.16
Forward PE	1048.80	293.05	117.15	261.09	112.30	65.12
P/FCF Ratio	-	-	253.93	82.47	40.22	-
PS Ratio	17.28	14.32	14.11	16.65	8.20	10.61